Clinical trial
Galantamine for Cognition in People With Schizophrenia
NCT00320736 · North Suffolk Mental Health Association, Other · Completed
Key facts
| NCT number | NCT00320736 |
|---|---|
| Title | Galantamine for Cognition in People With Schizophrenia |
| Official title | Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder |
| Lead sponsor | North Suffolk Mental Health Association, Other |
| Collaborators | Janssen Medical Affairs Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | galantamine |
| Enrollment | 20 |
| Start date | Jan 1, 2004 |
| Completion | May 1, 2006 |
| First posted | May 3, 2006 |
| Last update posted | May 19, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: